Large-scale generation and integration of genomic, proteomic and metabolomic data are increasingly allowing the construction of complex networks that provide a new framework for understanding the molecular basis of disease states. This Opinion article highlights how this knowledge could be applied to network-based drug discovery to investigate the impact of interventions — such as candidate drugs — on the molecular networks that define these states, and could ultimately be used to develop improved therapies.
- Eric E. Schadt
- Stephen H. Friend
- David A. Shaywitz
